基因检测在新型口服抗凝药物个体化治疗中的应用  

Application of gene detection in individualized treatment with new oral anticoagulant drugs

作　　者：刘学 李容 谢星星 余志刚[1] Liu Xue;Li Rong;Xie Xingxing;Yu Zhigang(Department of Pharmacy,Ya'an People's Hospital,Ya'an 625099,China)

机构地区：[1]雅安市人民医院药剂科,四川雅安625099

出　　处：《实用药物与临床》2024年第9期701-706,共6页Practical Pharmacy and Clinical Remedies

基　　金：四川省科技厅科技计划苗子工程重点项目(2022JDRC0146);雅安市重点科技计划-应用技术研究与开发面上项目(22KJJH0039);北京医学奖励基金会科研项目(YXJL-2023-0866-0316)。

摘　　要：新型口服抗凝药物(New oral anticoagulants,NOACs)已广泛应用于血栓栓塞性疾病的预防和治疗,个体差异、基因因素等是影响其临床合理使用的关键。因此,有必要对患者进行基因检测,从而指导NOACs的个体化用药。本文主要概述了NOACs的个体化治疗,并介绍了基因多态性对NOACs治疗效果的影响,以及在药物基因组学模型中借助基因检测指导临床NOACs个体化治疗的应用。New oral anticoagulants(NOACs)have been widely used in the prevention and treatment of thromboembolic diseases.Individual differences and genetic factors are the key factors affecting their clinical rational use.Therefore,it is necessary to carry out gene detection on patients,so as to guide the individualized medication of NOACs.This article mainly summarizes the individualized treatment with NOACs,and introduces the influence of genetic polymorphisms on the treatment effect of NOACs,as well as the application of gene detection to guide the individualized clinical treatment with NOACs in the pharmacogenomics model.

关 键 词：基因检测 新型口服抗凝药物 基因多态性 个体化治疗 

分 类 号：R973.2[医药卫生—药品]